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Purpose: To describe the use of a pumpless extracorporeal 
lung assist device in the treatment of severe acute respiratory 
distress syndrome (ARDS).
Clinical features: A 15-yr-old girl developed severe post-trau-
matic ARDS. After all conventional treatment strategies failed, 
we inserted a pumpless extracorporeal lung assist device. This 
device consists of an arterial cannula inserted into the femoral 
artery, and a membrane oxygenator with a venous cannula that 
returns the oxygenated blood back to the patient’s femoral 
vein. Since the driving force is the patient’s blood pressure, a 
roller pump with its negative side effects is not needed. The 
device allowed removal of excessive PaCO2 and, by applying 
minimal ventilation, minimization of further ventilator-induced 
lung injury. The pumpless extracorporeal lung assist device 
remained in situ for ten days without any adverse side effect. 
During this time, the lung recovered such that mechanical 
ventilation could be reinstalled cautiously. The device was then 
removed and, after a prolonged period of intensive care, the 
patient recovered without any sequelae. 
Conclusion: In this case of a severely damaged lung, an arte-
riovenous pumpless extracorporeal lung assist was a helpful 
device to remove elevated CO2 and reduce mechanical stress 
by applying minimal ventilation. This device is simple to operate 
and has the potential of being used routinely in the treatment 
of severe ARDS.
Objectif : Décrire l’usage d’un appareil d’assistance respiratoire 
extracorporelle sans pompe dans le traitement d’un syndrome de 
détresse respiratoire aiguë (SDRA) sévère.
Éléments cliniques : Un SDRA post-traumatique sévère s’est 
développé chez une jeune fille de 15 ans. Après l’échec de toutes 
les stratégies habituelles de traitement, nous avons inséré un 
appareil d’assistance respiratoire extracorporelle sans pompe. 
Cet appareil comprend une canule artérielle insérée dans l’artère 
fémorale et un oxygénateur à membrane avec une canule veineuse 
qui retourne le sang oxygéné dans la veine fémorale du patient. 
Comme la force d’entraînement est la tension artérielle du patient, 
une pompe à rouleaux, qui présente des effets secondaires négatifs, 
n’est pas nécessaire. L’appareil permet le retrait de la PaCO2 exces-
sive et, en appliquant une ventilation minimale, la réduction d’une 
lésion respiratoire supplémentaire induite par la ventilation méca-
nique. L’appareil est demeuré in situ pendant dix jours sans aucun 
effet secondaire indésirable. Pendant cette période, le poumon s’est 
rétabli de sorte que la ventilation mécanique a pu être réinstallée 
prudemment. L’appareil a ensuite été retiré et, après une période 
prolongée de soins intensifs, la récupération de la patiente a été 
sans séquelles.
Conclusion : Dans ce cas d’atteinte respiratoire sévère, une assis-
tance respiratoire artérioveineuse extracorporelle sans pompe a été 
très utile pour éliminer le CO2 élevé et réduire le stress mécanique 
en appliquant une ventilation minimale. Cet appareil est d’usage 
simple et peut être utilisé de routine dans le traitement du SDRA 
sévère.
A
CUTE respiratory distress syndrome 
(ARDS) is a potentially lethal disease with 
a mortality of up to 50%.1 Despite many 
efforts to improve outcome, there is little 
evidence for successful new therapies. Lung protec-
tive ventilation1 is the only evidence-based clinical 
treatment,2 whereas positive end-expiratory pressure3 
permits spontaneous breathing,4 prone positioning,5 
inhaled nitric oxide,6 immunomodulating enteric 
nutrition,7 and glucocorticoids in the late phase of 
severe ARDS, are all interventions that do not show 
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a clear improvement in outcome. Extracorporeal 
membrane oxygenation (ECMO) is a controversial 
treatment for ARDS. Extracorporeal membrane oxy-
genation is used as a last effort in very severe cases, 
and its application is limited to specialized medi-
cal centres.8 Risks and complications of ECMO are 
numerous: bleeding, infections, hemolysis, throm-
bosis of the system, and plasma leakage are observed 
most frequently. Recently, a pumpless arteriovenous 
gas exchange device was developed (NovaLung™, 
GmbH, Hechingen, Germany) that uses a membrane 
with a very low flow resistance.9 It allows complete 
removal of arterial CO2 and significant oxygenation of 
the arterial blood. We report its successful use in the 
treatment of ARDS in a 15-yr-old girl. Consent for 
publication was obtained from the patient’s mother in 
accordance with our Institutional guidelines.
Case report
While hiking, a previously healthy 15-yr-old girl fell 
15 meters down a rock face. Because of respiratory 
distress and a Glasgow coma score of 10, her trachea 
was intubated at the scene. In the emergency room, a 
chest x-ray revealed small bilateral pneumothoraces, a 
white lung on the right side, and lung contusions on 
the left. Further diagnostic evaluation revealed small 
brain contusions and a fracture of the right lower 
leg. Hemodynamic parameters were stable, ultraso-
nography of the abdomen was normal, and her skull 
and spine were not injured. Accordingly, one chest 
drain on the left side and two on the right side were 
inserted. The small endotracheal tube was replaced by 
an early tracheotomy and, finally, the fractured tibia 
was stabilized by external fixation.
A few days after her arrival in the intensive care 
unit, a multiple organ dysfunction syndrome occurred 
with renal failure, ARDS, and hemodynamic instabil-
ity. Two weeks after recovery from multiple organ 
dysfunction syndrome, a bacterial pneumonia evolved, 
and a second, and more severe case of ARDS devel-
oped. It was necessary to reinsert pleural drainage on 
both sides due to ventilator-induced pneumothoraces. 
Despite pressure-controlled ventilation, high respira-
tory rate and low-tidal volumes, prone positioning, 
inhaled bronchodilators, and inhaled nitric oxide, the 
blood gases and lung compliance continuously dete-
riorated. Application of higher levels of positive end-
expiratory pressure failed due to a dramatic increase 
of air leakage through the pleural drainages. During 
this time, the patient was sedated to a sedation agita-
tion score of 1 with high doses of midazolam (300 
µg·min–1 iv) and morphine (100 µg·min–1 iv). No 
muscle relaxants were administered. When arterial 
blood gas analysis showed a critical PaO2 of 60 mmHg 
(FIO2 1.0), a PaCO2 of 145 mmHg, and all conven-
tional therapeutic efforts were exhausted; we decided 
to use a new lung assist device (NovaLung™) as a last 
attempt to save the patient (Figure). The Table pres-
ents the course of blood gas analyses and the respira-
tory parameters before and after the introduction of 
this device.
We inserted two 13-French cannulae into the 
femoral artery and vein, and connected them to the 
prefilled membrane oxygenator (Quadrox Spezial, 
Jostra Inc., Hirrlingen, Germany). After the extra-
corporeal circulation was instituted, the passive flow 
measured in the venous part of the system was 1.2 
L·min–1 and the patient’s blood pressure and heart 
rate remained unchanged. Oxygen saturation mea-
sured by pulse oximetry and PaO2 did not change. 
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FIGURE  This extracorporeal, pumpless lung assist device 
consists of an arterial and a venous cannula and the mem-
brane oxygenator. The driving force is the arteriovenous 
pressure gradient of the patient’s blood. Before insertion 
of the cannulae using Seldinger’s technique, the internal 
diameters of the common femoral artery and vein have to 
be estimated by ultrasound. After insertion, the cannulae 
are clamped and connected to the prefilled tubing system 
containing the membrane oxygenator (Quadrox Spezial). As 
the total extracorporeal length (tip-to-tip) does not exceed 
120 cm, no heat exchanger is needed. An O2 supply line is 
connected to the inflow site of the membrane oxygenator 
with an O2 flow of 4 to 12 L·min
–1. A continuous heparin 
infusion is connected to the arterial cannula to keep the 
activated clotting time at a level of 130 to 150 sec. A bidi-
rectional ultrasound sensor is placed at the outflow line to 
determine the extra corporeal flow.
We then started O2 flow at 6 L·min
–1. At this point, 
arterial blood gas analyses were taken every five to 
ten minutes to adjust for the reduction in arterial 
PaCO2. Heparin was applied continuously to achieve 
and maintain an activated clotting time of 120 to 
150 sec. The next step was the most critical. We tried 
to establish “apneic oxygenation” by reducing tidal 
volume and respiratory rate progressively. It required 
approximately six hours to reach stable conditions, 
and during this time O2 saturation decreased multiple 
times to values below 85%. As we were not able to 
reach apneic oxygenation, we finally set the respira-
tory rate at 4 breaths·min–1; conventional biphasic 
positive airway pressures were 22 and 26 cm H2O 
with an FIO2 of 1.0 and nitric oxide was applied at 8 
ppm. Gas exchange gradually improved (Table), and 
hemodynamic parameters, diuresis, and temperature 
(37°C) remained stable. 
We did not change the ventilator settings over the 
course of the next five days, with the exception that 
FIO2 was carefully reduced to 0.7, and the patient 
was gradually weaned off the nitric oxide. The seda-
tion level was then reduced, spontaneous respiration 
gradually resumed, the patient awakened. On day 
eight following insertion of the lung assist device, the 
expiratory pressure level was reduced step by step to 
14 cm H2O with a mechanical respiratory rate of 25 
breaths·min–1. On day ten, FIO2 was 0.4, expiratory 
pressure level was decreased to 12 cm H2O, inspira-
tory pressure level was unchanged at 26 cmH2O and 
mechanical respiratory rate was 25 breaths·min–1. 
Blood flow through the NovaLung™ device was 
always between 0.9 and 1.2 L·min–1. We next stopped 
the O2 supply to the membrane oxygenator and, as 
there was no change in arterial PaCO2, a surgeon 
removed the cannulae and sutured the insertion sites 
of the vessels. The following weeks were complicated 
by several episodes of sepsis; but 104 days after admis-
sion our patient was transferred to a peripheral hos-
pital, and ten weeks later she returned home without 
any further sequelae.
Discussion
Our case describes a young girl suffering from severe 
post-traumatic ARDS. Conventional and new thera-
peutic strategies were not effective, resulting in very 
high arterial PaCO2 levels with corresponding respira-
tory acidosis and low, but not yet life-threatening PO2 
levels. Additionally, pleural leakage of air complicated 
mechanical ventilation. When PaCO2 intermittently 
rose to levels as high as 145 mmHg and oxygenation 
deteriorated further, we decided to apply an extra-
corporeal gas exchange device. Because our univer-
sity hospital does not provide pump-driven ECMO 
and the patient was not in a transferable state, the 
NovaLung™ device was the only available option. 
This technique is attractive because of its simplic-
ity and independence from machines. It is based on 
a low resistance lung assist device designed for pul-
satile blood flow with tight diffusion membranes and 
a protein matrix coating. The gas exchange surface 
amounts to 1.3 m2. Blood-flow resistance across the 
membranes is reduced to an arteriovenous pressure 
gradient of approximately 15 mmHg between inflow 
and outflow of the system, with pressure gradient 
being cannulae dependent but providing a trans 
device blood flow of up to 4 L·min–1.10 The rationale 
for using such a device was not primarily to improve 
oxygenation, but more to minimize ventilator-associ-
ated lung injury, and to ameliorate and eliminate the 
inflammatory process that is enhanced by mechani-
cal ventilation. With this method, complete removal 
of CO2 is possible within minutes by increasing O2 
flow, but the drop in CO2 should be guided by the 
change in pH. PaO2 values did not change after extra-
corporeal circulation was initiated, and an O2 flow of 
6 L·min–1 was applied, but fell dramatically when we 
tried to incorporate apneic ventilation. 
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TABLE  Respiratory parameters
 Before PECLA Day 2 PECLA Day 5 PECLA Day 8 PECLA Day 10 PECLA
Vte (mL) 160 225 250 300 320
MVe (L·min
–1) 6.7 0.9 1.0 7.5 8.0
RRmech 42 4 4 25 25
PaO2 (mmHg)/FIO2 61 164 134 188 352
PaCO2 (mmHg) 145 56 56 50 55
pH 7.08 7.38 7.42 7.47 7.41
PECLA = pumpless extracorporeal lung assist; Vte = expiratory tidal volume; MVe = expiratory minute volume; RRmech = mechanical respi-
ratory rate.
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There might be several reasons for the observed 
decrease in PaO2. First, a blood flow of 1 L·min
–1 
through the membrane oxygenator is quite low. This 
equals about 25% of the patient’s cardiac output. The 
membrane oxygenator of the NovaLung™ device is 
based on the Quadrox™ heparin coated hollow fibre 
technology. Its low resistance produces a pressure 
gradient of only 10 to 15 mmHg between inflow and 
outflow, providing a transmembrane oxygenator flow 
of up to 4 L·min–1, depending on the diameters of 
the cannulae. Since we were treating a young teen-
ager with a femoral artery diameter of only 5 mm, 
we had to insert a small 13-French cannula, resulting 
in a correspondingly low blood flow. Secondly, it is 
more difficult to oxygenate arterial blood than to use 
unsaturated venous blood, as is done in venovenous 
ECMO systems. Thirdly, the decrease of oxygen 
pressure in the blood was most prominent after we 
stopped ventilation completely, which caused the 
concentration of the simultaneously applied nitric 
oxide to increase and probably resulted in a further 
ventilation-perfusion mismatch. Once the increase 
was noted, it was resolved by providing minimal 
ventilation with a respiratory rate of 4 breaths·min–1, 
with inspiratory and expiratory pressures of 26 and 
22 cm H2O, respectively. After resolution, the con-
centrations of nitric oxide and arterial PaO2 remained 
stable. During the entire critical phase, the patient 
was ventilated in the biphasic positive airway pressure 
and assisted spontaneous breathing mode of an Evita 
4 respirator (Draeger, Lübeck, Germany). This mode 
consists of pressure-controlled ventilation with tube 
compensation that allows spontaneous breaths during 
the entire mechanical cycle. The spontaneous efforts 
of the patient are pressure supported with tube com-
pensation during the mechanical expiration phase.
Since the pulmonary parameters stabilized, we did 
not change the mechanical ventilatory settings for the 
next five days. Our intent was to allow the lungs to 
recover without the stress of repeated mechanical dis-
tension by the respirator. During this period, we only 
reduced FIO2 to 0.7, based upon the PaO2 values, 
and the patient was weaned off nitric oxide. Because 
there is little experience on the best method to wean 
a patient from such a lung assist device, we had to 
define one. After five uneventful days of apneic ven-
tilation, we reduced sedation and our patient began 
to spontaneously breathe with a respiratory rate of 
25 breaths·min–1. During the course of the next five 
days, we reduced the expiratory level of the bi-level 
positive airway pressure ventilation step-by-step to 14 
cm H2O. The mechanical respiratory rate was adapted 
to the patient’s initial spontaneous respiratory rate 
of 25 breaths·min–1. Thus, tidal volumes were care-
fully augmented. Finally, on the tenth day of using 
the membrane oxygenator, a bi-level positive airway 
pressure modus was set at an FIO2 of 0.4, inspiratory 
pressure level of 26 cm H2O, expiratory pressure level 
of 12 cm H2O, and a mechanical respiratory rate of 25 
breaths·min–1, which resulted in tidal volumes of 350 
to 400 mL and a minute volume of 8 to 9 L·min–1. 
After cessation of the external O2 supply to the mem-
brane oxygenator, arterial blood gases remained stable 
over several hours. At this time, we decided to remove 
the NovaLung™.
In conclusion, arteriovenous pumpless extracor-
poreal lung assist is a reasonable complementary 
therapeutic option in the treatment of severe ARDS. 
Insertion can be done by an intensivist and, after an 
initial intensive monitoring phase, the NovaLung� is 
a simple device to operate. Adverse events were not 
observed. Routine application in critically ill patients 
with ARDS appears possible, but future studies will be 
needed to demonstrate this, as well as to determine 
the indications that are optimal for its use. 
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